Format

Send to

Choose Destination
Yonago Acta Med. 2013 Jun;56(2):43-50. Epub 2013 Jul 12.

New strategy for overcoming resistance to chemotherapy of ovarian cancer.

Author information

1
Tottori University Hospital Cancer Center, Yonago 683-8504, Japan.

Abstract

BACKGROUND:

Ovarian cancer is one of the most sensitive solid tumors, with objective responses ranging from 60 to 80% even in patients with advanced stage. However, most patients ultimately recur and develop resistance to chemotherapy. As a result, the survival rate for patients with ovarian cancer has not improved over the past 20 years. Resistance to chemotherapy presents a major obstacle to attempt to improve the prognosis of patients with ovarian cancer. A new strategy is necessary to improve the prognosis of patients with ovarian cancer.

METHODS:

The mechanism of chemoresistance was reviewed to get over the resistance. Additionally, the biological characteristics of ovarian cancer and molecular-targeted agents including signal-transduction inhibitors and anti-angiogenesis were discussed.

RESULTS:

Genetic diagnosis for chemosensitivity with drug-resistance genes may be a useful predictor. Unfortunately, molecular-targeted therapy alone has been insufficient to improve the prognosis for patients with advanced ovarian cancer. Molecular molecular-targeted therapy should be carried out together with conventional cytotoxic agents. On the occasion of the use of the molecular targeted-agents, care of the appearance of the unexpected adverse effect should be important.

CONCLUSION:

The future research in this field will enable to develop an effective strategy for conquest of chemoresistance in ovarian cancer.

KEYWORDS:

chemotherapy;; molecular targeted agent; ovarian cancer; resistance

PMID:
24031151
PMCID:
PMC3771207

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center